Opparounds

Predicting Long-Term Poor Outcomes in Individuals at Clinical High Risk for Psychosis Using Real-World Clinical Data: The OASIS1000 Prospective Study

Logeswaran Y, De Micheli A, Toniol I, et al. · World Psychiatry · June 2026

This 21-year prospective cohort followed 1,000 patients at clinical high risk for psychosis (CHR-P) from a UK early-detection service, using routine clinical data to build a model predicting long-term poor outcomes — transition to psychosis, need for first-episode-level antipsychotic dosing, psychiatric hospitalization, or suicide — beyond the usual short transition-risk window. By 14–18 years, roughly 64% of CHR-P patients had experienced one of these outcomes, and the model showed useful discrimination (C=0.69) built entirely from data a clinic would already have on hand.

Read the paper →  doi:10.1002/wps.70063

Potential Mechanisms of Change in Virtual Reality-Based CBT and Standard CBT for Schizophrenia-Related Paranoia: A Mediation Analysis From the FaceYourFears Trial

Jeppesen UN, Vernal DL, Christensen MJ, et al. · Schizophrenia Bulletin Open · July 2026

This secondary mediation analysis of the 254-patient FaceYourFears trial — which found VR-guided CBT for psychosis (VR-CBTp) and standard CBTp equally effective — tested whether the two treatments work through different theorized mechanisms: safety behaviors, belief inflexibility, and negative core beliefs. None of the hypothesized differential-mediation effects held up in 186 completers: despite far more in-session exposure in the VR arm, safety-behavior change wasn't more influential there, and belief-inflexibility change wasn't more influential with standard CBTp. More in-session VR exposure was actually associated with slightly worse paranoia outcomes.

Read the paper →  doi:10.1093/schizbullopen/sgag028

Lamotrigine's Rash Risk Is a Titration Problem, Not a Dose Problem

Comparative data show rash rates dropping from roughly 27% to 8% when lamotrigine is titrated slowly instead of at the standard schedule, and Stevens-Johnson risk falls by one to two orders of magnitude with the same change — the driver is peak plasma concentration and rate of rise, not the eventual maintenance dose. This is also why the schedule changes with valproate on board: valproate inhibits the UGT enzymes that clear lamotrigine, roughly doubling levels for a given dose, so the co-administration titration is slower and lower than monotherapy. Most reactions surface in the first eight weeks. The practical consequence for a missed-dose restart: don't resume at the prior maintenance dose after any meaningful gap — restart the titration from the beginning, because the protection was never about the dose itself, it was about how slowly the patient got there.

Renegotiating the Contract Is Itself an Intervention, Not an Administrative Reset

TFP's treatment contract isn't signed once and filed away. When a patient begins missing sessions or repeatedly arrives too late for meaningful work, the technique is a tactical renegotiation of the frame, conducted in-session with the same clarification-confrontation logic used on any other material — not a hallway reminder of the rules. Kernberg's approach treats the boundary problem as data about which internal object relation is dominating the transference at that moment, rather than as a compliance issue to solve administratively. The renegotiation names the behavior concretely, links it to the pattern it belongs to, and invites the patient to help design the new limit — collaboration is what keeps the intervention therapeutic rather than punitive. Skipping straight to enforcement treats the frame as furniture instead of clinical material.